Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT04506138
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2020-09-09
- Target Recruit Count
- 74
- Registration Number
- NCT04506242
Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 117
- Registration Number
- NCT04498689
- Locations
- 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
- Conditions
- Interventions
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Jiangxi Provincial Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04481763
- Locations
- 🇨🇳
Chunling Jiang, NanCHang, Jiang XI, China
Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 34
- Registration Number
- NCT04479527
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Huiqiang Huang
- Target Recruit Count
- 33
- Registration Number
- NCT04476459
- Locations
- 🇨🇳
Department of Medical Oncology, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China
Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT04459078
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study
- Conditions
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT04454905
- Locations
- 🇨🇳
Li Xu, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT04443309
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, Please Select, China
Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2021-02-02
- Target Recruit Count
- 32
- Registration Number
- NCT04440917
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.